Translate Bio to Participate in Upcoming Investor Conferences
Translate Bio (Nasdaq: TBIO) announced its participation in two upcoming investor conferences. The CEO, Ronald Renaud, will engage in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 10:30 a.m. ET, and at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 3:50 p.m. ET. A live webcast of these sessions will be available on the company's website, with replays accessible for 30 days post-event. Translate Bio focuses on mRNA therapeutics, particularly for pulmonary diseases, and collaborates with Sanofi Pasteur on mRNA vaccines.
- None.
- None.
LEXINGTON, Mass., May 24, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced that the Company will participate in the following upcoming investor conferences:
- Jefferies Virtual Healthcare Conference: Ronald Renaud, chief executive officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 10:30 a.m. ET.
- Goldman Sachs 42nd Annual Global Healthcare Conference: Ronald Renaud, chief executive officer, will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 3:50 p.m. ET.
A live webcast of the session will be accessible through the “Events and Presentations” page of the Company's website at investors.translate.bio. A replay of the webcasts will be archived on the Translate Bio’s website for 30 days following the presentation.
About Translate Bio
Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases with a lead pulmonary candidate being evaluated as an inhaled treatment for cystic fibrosis (CF) in a Phase 1/2 clinical trial. Additional pulmonary diseases are being evaluated in discovery-stage research programs that utilize a proprietary lung delivery platform. Translate Bio also believes its technology may apply broadly to a wide range of diseases, including diseases that affect the liver. Additionally, the platform may be applied to various classes of treatments, such as therapeutic antibodies or protein degradation. Translate Bio is also pursuing the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur. For more information about the Company, please visit www.translate.bio or on Twitter at @TranslateBio.
Contacts for Translate Bio
| Investors | Media | |
| Teri Dahlman | Maura Gavaghan | |
| tdahlman@translate.bio | mgavaghan@translate.bio |
FAQ
When will Translate Bio participate in the Jefferies Virtual Healthcare Conference?
What is the date of the Goldman Sachs 42nd Annual Global Healthcare Conference for Translate Bio?
Who is the CEO of Translate Bio participating in the conferences?
Where can I watch the webcasts of Translate Bio's presentations?
What is the main focus of Translate Bio's research?
